Plain-English translation of NCT06428097 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
After a heart transplant, your body faces significant stress and challenges. This trial is testing whether , a thyroid hormone medication, can help heart transplant recipients recover better and live longer after surgery. Research from previous studies suggests the medication might improve survival rates, but this trial will be the first to test this idea rigorously in a controlled setting.
While doctors have noticed that giving this medication to heart transplant donors seems helpful, it's not yet standard practice to give it to recipients who don't already have thyroid problems. Two large studies hinted that the medication might improve survival after transplant, but researchers need a proper clinical trial to confirm whether it really works.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to receive either the thyroid hormone medication or a placebo (a dummy pill with no active ingredient) after your heart transplant. Neither you nor your doctors will know which group you're in — that's what makes it 'double-blinded.' You'll take your assigned pill regularly as part of your post-transplant care, and the research team will monitor your health outcomes to see if the medication helps you recover and survive better than the placebo group.
AI-generated summary from trial data · Aug 22, 2026 · Not medical advice
United States